PFD report

Tung Thanh Tran · Prevention of Future Deaths report

Pin Get email alerts Request correction

Issued 11 May 2026•Inner North London

Report record

Published report and response evidence

This page connects the concerns raised in this report with statements found in recipients’ published responses. A link shows a clear evidence connection; it does not assign responsibility.

View original report
Concerns
2

Raised in this report

Recipients
2

Named on the report

Responses found
1

Of 2 recipients

Stated actions
2

Described in responses

Recipients and published responses

Source document

Full report text

This is the full text from the original published report.

Open published report

Concerns and recipient responses

Select any concern, action or position to view the source wording.

Concerns raised2

  1. Lack of national guidance on responsibility for hepatitis B reactivation prevention monitoring and prescribing
  2. Lack of specialised commissioning to maintain subsequent engagement with services after hepatitis B infection is identified through Emergency Department opt-out screening
Responses linked to these concerns

Each statement is shown once, even when linked to more than one concern.

Respondent positions A position is what a recipient says about a concern when it does not describe a specific action.2

  1. Position

    Clinical guideline development and publication are outside the association’s remit.

    Stated by The British Association for the Study of the LiverOutside remitThe respondent said that this matter was outside its role or authority.

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Lack of national guidance on responsibility for hepatitis B reactivation prevention monitoring and prescribing

Wider context from the report

“1. There is a lack of national guidance regarding which services should be responsible for the monitoring and prescribing in relation to hepatitis B reactivation prevention; (concern directed to BASL) ”

Is this part of a recurring concern?

No recurring-concern membership is currently published.

Open source report

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Lack of specialised commissioning to maintain subsequent engagement with services after hepatitis B infection is identified through Emergency Department opt-out screening

Wider context from the report

“2. There is a large population of patients who are found to have hepatitis B infection through opt-out screening in Emergency Departments but there is a lack of specialised commissioning to maintain subsequent engagement with services. I heard that this differs from the position with regards to hepatitis C and HIV services, even though these patient populations are smaller (concern directed to UKHSA) ”

Is this part of a recurring concern?

No recurring-concern membership is currently published.

Open source report

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Clinical guideline development and publication are outside the association’s remit.

Verbatim wording from the response

“The British Viral Hepatitis Group (BVHG) is a sub-group of the British Association for the Study of the Liver (BASL). BASL is a charitable specialist society dedicated to advancing knowledge and understanding of liver diseases and to the optimal care of patients with those diseases. These aims are principally achieved through dissemination of research and sharing of clinical expertise and through the promotion of opportunities for collaboration in liver research. BASL does not lead the development or publication of clinical guidelines.”

Source location

Response from British Association for the study of the Liver
Page 1 · response
Published 10 July 2026

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

For hepatitis B core antibody-positive patients, monitoring and prescribing responsibility lies with treating teams or hepatology services under local arrangements.

Verbatim wording from the response

“• The second group is those patients who are HBsAg negative but hepatitis B core antibody (HBcAb) positive. These patients are at risk of hepatitis B reactivation in the setting of immunosuppressive treatment. There are many different specialties who prescribe immunosuppressive regimens, including (but not limited to) haematology, oncology, and non-liver organ transplant services. Guidance regarding the need for antiviral therapy for such patients is provided by the relevant specialist societies and frequently also in local NHS Trust guidance. There is variation between NHS Trusts as to whether this monitoring and prescribing is delivered by the treating team or whether specialist hepatology services are involved.”

Source location

Response from British Association for the study of the Liver
Page 1 · response
Published 10 July 2026

Open published response

Other statements in published responses

These actions and other statements could not be clearly connected to one concern in this report.

Recipient-stated actions An action is something a recipient says it has done, is doing, or plans to do in response to a concern raised.2

  1. 1

    Continue highlighting health inequalities and access-to-care issues affecting people living with viral hepatitis infections.

    Stated by The British Association for the Study of the LiverStated in progressThe respondent said that this action was in progress when they made their response on 10 July 2026.
  2. 2

    Incorporate hepatitis B reactivation risks, prevention and management into upcoming webinars and conferences, highlighting monitoring and antiviral-prescribing gaps.

    Stated by The British Association for the Study of the LiverStated plannedThe respondent said that this action was planned when they made their response on 10 July 2026.

Recipient positions A position is what a recipient says about a concern when they do not describe a specific action.1

  1. 1

    For chronic hepatitis B, specialist hepatology services are responsible for monitoring and prescribing antiviral therapy.

    Stated by The British Association for the Study of the LiverRedirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Continue highlighting health inequalities and access-to-care issues affecting people living with viral hepatitis infections.

Verbatim wording from the response

“Additionally, we will continue to highlight the role of health inequalities and access to care that also appears to have impacted the outcome in this case as we recognise these as being major issues for people living with viral hepatitis infections more widely.”

Source location

Response from British Association for the study of the Liver
Page 2 · response
Published 10 July 2026

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Incorporate hepatitis B reactivation risks, prevention and management into upcoming webinars and conferences, highlighting monitoring and antiviral-prescribing gaps.

Verbatim wording from the response

“• In line with the educational role of BASL and BVHG we have previously and will again incorporate the risks of hepatitis B reactivation and its prevention and management into our webinar and conference programmes in this coming year. We will use this forum to highlight the risks of gaps in monitoring and prescribing of antiviral treatment for participants to take back to their local services.”

Source location

Response from British Association for the study of the Liver
Page 2 · response
Published 10 July 2026

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

For chronic hepatitis B, specialist hepatology services are responsible for monitoring and prescribing antiviral therapy.

Verbatim wording from the response

“• The first is those patients with a diagnosis of chronic hepatitis B (CHB) defined by the presence of a positive hepatitis B surface antigen (HBsAg) on two occasions 6 months apart. These CHB patients are usually managed in specialist hepatology services and the responsibility of monitoring and prescribing lies with these services.”

Source location

Response from British Association for the study of the Liver
Page 1 · response
Published 10 July 2026

Open published response
Back to top

Information checked against the published report and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Data last updated 7 September 2026